Oramed (ORMP) COO Joshua Hexter Receives Restricted Stock Awards

What Happened

• Joshua Hexter, Chief Operating Officer & Chief Business Officer of Oramed Pharmaceuticals (ORMP), received restricted stock awards (RSAs) on September 24, 2026: 75,455 shares that fully vested on grant (valued at $4.75/sh = ~$358,411) and an additional 209,291 RSAs (40% vested at grant; remaining 60% vest quarterly over 24 months). On the same date he had three derivative dispositions to the issuer totaling 136,000 shares (50,000; 50,000; 36,000), recorded as dispositions to the issuer (derivative).

Key Details

• Transaction date: September 24, 2026 (filed on Sep 25, 2026 — timely).
• Awards: 75,455 RSAs fully vested (valued at $4.75/share, closing price 9/22/2026); 209,291 RSAs subject to vesting (40% immediate, 60% in 8 equal quarterly installments over 24 months).
• Dispositions: Three derivative dispositions to issuer totaling 136,000 shares (listed as "Disposition to the issuer (Derivative)"); no per-share price shown for these dispositions in the filing.
• Shares owned after transaction: Not specified in the filing.
• Notable footnotes: Option exchange program approved by a committee of non‑employee directors; the 75,455 RSAs represent exchange value equal to the Black‑Scholes value of canceled options. Footnotes also detail original option vesting schedules and that 50,000 of the previously vested options had been exercised earlier.

Context

• These transactions reflect an option exchange program: certain outstanding options were canceled and replaced with RSAs (one award fully vested at grant; the larger award mostly time‑based vesting). The derivative "dispositions to the issuer" relate to the option cancellation/exchange process as disclosed in the footnotes.
• This is compensation/retention activity rather than an open‑market purchase or sale; such awards are common for executives and do not necessarily signal an immediate buy/sell view of the stock.